A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

Author: Arnoletti J.   Frolov A.   Eloubeidi M.   Keene K.   Posey J.   Wood T.   Greeno Edward   Jhala N.   Varadarajulu S.   Russo S.   Christein J.   Oster R.   Buchsbaum D.   Vickers S.  

Publisher: Springer Publishing Company

ISSN: 0344-5704

Source: Cancer Chemotherapy and Pharmacology, Vol.67, Iss.4, 2011-04, pp. : 891-897

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next